Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $17.00 Consensus Target Price from Analysts

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have been given an average recommendation of “Reduce” by the four brokerages that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $17.00.

Several research firms have recently weighed in on VRCA. Zacks Research cut Verrica Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 7th. Wall Street Zen lowered Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, TD Cowen reissued a “buy” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, January 7th.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Man Group plc acquired a new stake in Verrica Pharmaceuticals in the 4th quarter valued at approximately $94,000. Quadrature Capital Ltd acquired a new stake in Verrica Pharmaceuticals in the 4th quarter valued at approximately $99,000. Bridgeway Capital Management LLC acquired a new stake in Verrica Pharmaceuticals in the 3rd quarter valued at approximately $52,000. Beck Mack & Oliver LLC acquired a new stake in Verrica Pharmaceuticals in the 4th quarter valued at approximately $100,000. Finally, XTX Topco Ltd acquired a new stake in Verrica Pharmaceuticals in the 4th quarter valued at approximately $122,000. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Price Performance

Shares of VRCA stock opened at $6.49 on Friday. The stock has a 50-day moving average price of $5.64 and a 200 day moving average price of $6.03. The company has a quick ratio of 2.45, a current ratio of 2.59 and a debt-to-equity ratio of 0.03. The firm has a market cap of $111.50 million, a price-to-earnings ratio of -4.11 and a beta of 1.42. Verrica Pharmaceuticals has a 12 month low of $3.28 and a 12 month high of $9.82.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings data on Wednesday, March 11th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.08). The firm had revenue of $5.09 million during the quarter, compared to analyst estimates of $4.52 million. Research analysts expect that Verrica Pharmaceuticals will post -2.24 EPS for the current year.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off?label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next?generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.